<a href="https://www.fiercebiotech.com/medtech/e2-lands-80m-series-c-next-gen-thrombectomy-treatment" hreflang="en">E2 lands $80M series C for next-gen thrombectomy treatment </a>
fiercebiotech.com·Apr 7, 2026
California medtech E2 has secured $80 million in a Series C funding round to advance the commercialization of its pulmonary embolism treatment.
For a professional tracking healthtech and medtech investments, the key takeaway is that E2's successful $80 million Series C funding round signals strong investor confidence in their pulmonary embolism treatment, highlighting a significant commercial opportunity in the medtech field. This could indicate a trend or opportunity for further investment or partnerships in the pulmonary and cardiovascular treatment space.